Core Viewpoint - Northstrive Biosciences has entered into a Development and License Agreement with Yuva Biosciences to develop novel pharmaceutical treatments for obesity, type 2 diabetes, and other cardiometabolic conditions using YuvaBio's AI-powered mitochondrial science platform MitoNova [1][2][7] Group 1: Agreement Details - The Agreement involves collaboration on an AI Development Program where YuvaBio will develop technology related to mitochondrial science and identify drug candidates to improve mitochondrial health and cardiometabolic function [2][3] - YuvaBio will grant Northstrive an exclusive, worldwide license to the developed technology for therapeutic products targeting cardiac diseases and obesity [2][5] Group 2: AI Development Program - The AI Development Program will utilize YuvaBio's proprietary AI platform combined with laboratory validation to identify and advance novel drug candidates that target mitochondrial function [3][4] - The collaboration will include phases such as in silico modeling, virtual compound screening, and experimental testing to shortlist promising candidates for clinical development [3][4] Group 3: Financial Terms - In exchange for the rights and license, YuvaBio will receive an upfront fee, milestone payments based on program phases, and royalties on net sales of certain therapeutic products developed by Northstrive [5]
Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases